Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT04096690
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
- Conditions
- Interventions
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 36
- Registration Number
- NCT03962465
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Bone ScanDrug: CyclophosphamideProcedure: Computed TomographyDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: CytarabineDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumBiological: Inotuzumab OzogamicinDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseProcedure: Magnetic Resonance ImagingDrug: PrednisoloneOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Positron Emission TomographyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 4997
- Registration Number
- NCT03959085
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiDrug: CyclophosphamideBiological: BlinatumomabDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: Mercaptopurine Oral SuspensionDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: PrednisoloneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Wei Zhao
- Target Recruit Count
- 1500
- Registration Number
- NCT03844360
- Locations
- 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03808610
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT03792256
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Conditions
- Interventions
- Drug: BortezomibDrug: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: MyocetDrug: DoxorubicinDrug: 6-MercaptopurineDrug: EtoposideDrug: Fludarabine PhosphateDrug: PrednisoloneDrug: IfosfamideDrug: TioguaninDrug: PegaspargaseDrug: MethotrexateDrug: ErwinaseDrug: VincristineDrug: Vindesine
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Martin Schrappe
- Target Recruit Count
- 5000
- Registration Number
- NCT03643276
- Locations
- 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹S.O. Annunziata - A. O. Cosenza, Cosenza, Italy
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: RuxolitinibDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: VincristineDrug: PegaspargaseDrug: RituximabDrug: Methotrexate (Intrathecal Administration)Drug: Methotrexate (Intravenous Administration)Drug: DexamethasoneDrug: DoxorubicinDrug: ThioguanineDrug: Methotrexate Oral Product
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
- Conditions
- Interventions
- Drug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-mercaptopurine.Drug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: KaryotypingDrug: ChidamideDiagnostic Test: PET-CT scan
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT03564704
- Locations
- 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.